×
ASH News Daily
http://www.hematology.org/Annual-Meeting/AND.aspx

Nov 7th, 2018 - ASH News Daily is the official print publication of the ASH annual meeting. View an archive of recent ASH News Daily publications

ASH 2018 coming attractions look at the big picture
https://www.mdedge.com/hematologynews/article/189383/aggressive-lymphomas/ash-2018-coming-attractions-look-big-picture

Nov 21st, 2018 - Big trials, big results in malignant and nonmalignant hematologic disorders are on the program at the 2018 ASH annual meeting.

What's Hot at This Year's ASH Meeting?
https://www.medscape.com/viewarticle/905521

Nov 23rd, 2018 - The premier event in hematology is celebrating its diamond anniversary. This will be the 60th annual meeting of the American Society of Hematology (ASH). It will be returning to the city of San Diego, California, and will run from November 30 to December 4.

Every Patient Tells a Story: Using Narrative Medicine to Cure Disease
https://www.ashclinicalnews.org/on-location/every-patient-tells-story-using-narrative-medicine-cure-disease/

Nov 21st, 2018 - As part of the Education Program at the 2018 ASH annual meeting, three physician-writers will offer their take on the intersection of storytelling, writing, and medicine – asking why doctors should care about the narrative, how the patient narrative informs treatment decisions, and how writing can be a tool for advocacy and change.

ASH-a-Palooza: Trainee Day. Reimagined
https://www.ashclinicalnews.org/on-location/ash-palooza-trainee-day-reimagined/

Nov 21st, 2018 - The “Trainee Day” that attendees may know from past annual meetings has been reimagined as ASH-a-Palooza – a new educational experience that will offer a relaxed, open learning environment for trainees in a festival-like setting with multiple opportunities for micro-learning. During breaks between sessions at Petco Park, trainees can enjoy ballpark-style food and are invited to visit informatio...

For the Love of the Lab: Interview with John E. Dick, PhD
https://www.ashclinicalnews.org/on-location/love-lab-interview-john-e-dick-phd/

Nov 21st, 2018 - John E. Dick, PhD, recipient of the 2018 Mentor Award in basic science, tells us about his career in the lab – from working at “the mecca of stem-cell research” to learning how to foster creativity in his own lab

60th ASH Annual Meeting & Exposition
http://www.hematology.org/Annual-Meeting/

Nov 7th, 2018 - The premier event in malignant and non-malignant hematology, the ASH annual meeting highlights the highest-caliber science and the most important areas of clinical progress in hematology.

ASH preview: Studies target CAR T-cell improvements
https://www.mdedge.com/hematologynews/article/189361/cellular-therapy/ash-preview-studies-target-car-t-cell-improvements

Nov 21st, 2018 - Ibrutinib and checkpoint inhibitors may improve the efficacy of chimeric antigen receptor (CAR) T-cell therapies, according to investigators in two separate studies.

Myeloma Expert Previews 2018 ASH Abstracts
https://www.onclive.com/conference-coverage/ash-2018/myeloma-experts-preview-2018-ash-abstracts

Nov 27th, 2018 - Ahead of the conference, multiple myeloma experts Sundar Jagannath, MBBS, and Ajai Chari, MD, selected the most pivotal abstracts in their field

CLL drug combinations induce MRD negativity
https://www.mdedge.com/oncologypractice/article/153998/cll/cll-drug-combinations-induce-mrd-negativity

Nov 12th, 2017 - The potential of two- and three-drug combinations to induce MRD-negative responses in CLL patients was demonstrated in multiple studies presented at ASH.

Azacitidine maintenance improves PFS in older AML patients
https://www.mdedge.com/oncologypractice/article/154131/aml/azacitidine-maintenance-improves-pfs-older-aml-patients

Nov 12th, 2017 - A randomized, multicenter trial sheds light on care of older AML patients after chemotherapy. A randomized, multicenter trial sheds light on care of older AML patients after chemotherapy. A randomized, multicenter trial sheds light on care of older AML patients after chemotherapy. A randomized, multicenter trial sheds light on care of older AML patients after chemotherapy. A randomized, multice...

PD-1 Inhibitor Cemiplimab Active in B-Lymphoid Malignancies
https://www.onclive.com/conference-coverage/ash-2017/pd1-inhibitor-cemiplimab-active-in-blymphoid-malignancies

Oct 12th, 2017 - Cemiplimab as a monotherapy and in combination with the monoclonal antibody REGN1979 demonstrated clinical activity in patients with B-cell non-Hodgkin lymphoma and Hodgkin lymphoma.

Mogamulizumab Significantly Improves PFS in CTCL
https://www.onclive.com/conference-coverage/ash-2017/mogamulizumab-significantly-improves-pfs-in-ctcl

Oct 12th, 2017 - The anti-CCR4 monoclonal antibody mogamulizumab reduced the risk of progression or death by 47% compared with vorinostat (Zolinza) in previously treated patients with cutaneous T-cell lymphoma.

Axi-Cel Plus Atezolizumab Active, Safe in DLBCL
https://www.onclive.com/web-exclusives/axicel-plus-atezolizumab-active-safe-in-dlbcl

Dec 1st, 2018 - The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.

BCMA Antibody-Drug Conjugate Reaches 60% Response in Myeloma
https://www.onclive.com/conference-coverage/ash-2017/bcma-antibodydrug-conjugate-reaches-60-response-in-myeloma

The B-cell maturation antigen antibody-drug conjugate GSK2857916 induced an overall response rate of 60% in heavily pretreated patients with multiple myeloma.

With So Many Options, Best CLL Treatment May Be a Clinical Trial
http://www.medscape.com/viewarticle/891278

Combination regimens in CLL are already impressive, but new combinations currently being evaluated have strong potential to be even better.

Zanubrutinib Highly Active in Non-Hodgkin Lymphoma
https://www.onclive.com/conference-coverage/ash-2017/zanubrutinib-highly-active-in-nonhodgkin-lymphoma

Sep 12th, 2017 - The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma.

CAR T Cells in Advanced R/R Lymphoma: Keeping Patients Alive
http://www.medscape.com/viewarticle/889874

Nov 12th, 2017 - New longer-term data on CAR T cells in patients with refractory and relapsed (R/R) lymphoma show that responses are durable, with about half of patients alive after a year or more.

Venetoclax/Rituximab Hits Over 80% 2-Year PFS Rate in CLL
https://www.onclive.com/conference-coverage/ash-2017/venetoclaxrituximab-hits-over-80-2year-pfs-rate-in-cll

Dec 12th, 2017 - The combination of venetoclax and rituximab reduced the risk of disease progression or death by 83% versus bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. 

Atezolizumab Triplet Achieves 75% CR Rate in Frontline Follicular Lymphoma
https://www.onclive.com/conference-coverage/ash-2017/atezolizumab-triplet-achieves-75-cr-rate-in-frontline-follicular-lymphoma

Nov 12th, 2017 - The frontline combination of atezolizumab, obinutuzumab, and bendamustine, achieved a complete response in 75% of patients with follicular lymphoma, according to findings from a phase Ib/II trial.